Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FEIBA reduced-volume and faster-infusion tolerability study in hemophilia with inhibitors
2015-005781-39Phase 3Completed
- Sponsor
- Baxalta
- Start
- May 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of anti-inhibitor coagulant complex in hemophilia A and hemophilia B (HB), sponsored by Baxalta. Primary endpoint: Safety focus. Started May 2019; status: completed.
02
Drugs
anti-inhibitor coagulant complex
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on 2015-005781-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005781-39.